Med BioGene Inc. (TSX VENTURE:MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has entered into an agreement with Fraser Mackenzie Limited to act as exclusive lead agent in connection with a private placement (the "Private Placement") of $4 million of units. Subject to demand, the amount raised under the Private Placement may prior to closing be increased above $4 million.
